| Literature DB >> 35097167 |
Erfan Sheikhbahaei1, Seyed Peyman Mirghaderi2,3, Alireza Moharrami2, Danial Habibi4, Mehdi Motififard5, Seyed Mohammad Javad Mortazavi2.
Abstract
BACKGROUND: The safety of continuing total joint arthroplasty (TJA), as an elective procedure, during the pandemic is controversial. The present study aimed to investigate the incidence of symptomatic coronavirus disease 2019 (COVID-19) and its related risk factors in unvaccinated patients after TJA within 1 month after discharge in 2 large cities of our country.Entities:
Keywords: Arthroplasty; COVID-19; SARS-CoV-2; Safety
Year: 2022 PMID: 35097167 PMCID: PMC8784429 DOI: 10.1016/j.artd.2022.01.024
Source DB: PubMed Journal: Arthroplast Today ISSN: 2352-3441
The demographics, clinical information, and comorbidities of the patients.
| Variables | Postarthroplasty COVID-19 | ||
|---|---|---|---|
| Positive (N = 18) | Negative (n = 737) | ||
| Demographics | |||
| Age (y) | 63.94 ± 6.66 | 61.52 ± 12.60 | 0.15 |
| Female gender, n (%) | 15 (83.3%) | 546 (74.1%) | 0.37 |
| BMI (kg/m2) | 30.38 ± 6.24 | 28.58 ± 5.10 | 0.14 |
| Comorbidities | |||
| Diabetes, n (%) | 7 (38.9%) | 163 (22.1%) | 0.09 |
| Hypertension, n (%) | 9 (50.0%) | 347 (47.1%) | 0.81 |
| Pulmonary problem, n (%) | 4 (22.2%) | 47 (6.4%) | 0.008 |
| Renal disease, n (%) | 0 | 39 (5.3%) | 0.31 |
| Cardiovascular disease, n (%) | 4 (22.2%) | 122 (16.6%) | 0.79 |
| Immune system disease, n (%) | 2 (11.1%) | 68 (9.2%) | 0.78 |
| Cancer, n (%) | 1 (5.6%) | 18 (2.4%) | 0.41 |
| Clinical variables | |||
| Delayed surgery, n (%) | 1 (5.6%) | 97 (13.2%) | 0.343 |
| Delay duration (month) | 6.00 | 3.66 ± 2.96 | 0.43 |
| COVID-19 before surgery, n (%) | 1 (5.6%) | 67 (9.1%) | 0.98 |
| COVID-19 before surgery (months) | 2.00 | 4.67 ± 2.63 | 0.31 |
| Hospital, n (%) | |||
| Academic (N = 192, 25.4%) | 3 (16.7%) | 189 (25.6%) | 0.38 |
| Private (N = 563, 74.6%) | 15 (83.3%) | 548 (74.4%) | |
| City, n (%) | |||
| Isfahan (N = 483, 64%) | 12 (66.7%) | 471 (63.9%) | 0.81 |
| Tehran (N = 272, 36%) | 6 (33.3%) | 266 (36.1%) | |
| Joint; n (%) | |||
| Hip | 1 (5.6%) | 239 (32.4%) | 0.016 |
| Knee | 17 (94.4%) | 498 (67.6%) | |
| Surgery, n (%) | |||
| Primary | 18 (100%) | 674 (91.5%) | 0.19 |
| Revision | 0 | 63 (8.5%) | |
| Primary causes, n (%) | |||
| OA | 18 (100%) | 581 (78.8%) | 0.41 |
| DDH | 0 | 23 (3.1) | |
| AVN | 0 | 63 (8.5%) | |
| RA | 0 | 7 (1.0%) | |
| Revision causes, n (%) | |||
| Infection | 0 | 24 (3.3%) | - |
| Dislocation | 0 | 13 (1.8%) | |
| Periprosthetic fracture | 0 | 12 (1.6%) | |
| Aseptic loosening | 0 | 14 (1.9%) | |
| Hospital stay for arthroplasty | 2.83 ± 0.99 | 3.56 ± 1.62 | 0.06 |
BMI, body mass index; CI, confidence interval; OR, odds ratio; OA, osteoarthritis; DDH, developmental dysplasia of the hip; AVN, avascular necrosis; RA, rheumatoid arthritis.
Figure 1(a) The number of TJA procedures performed in the study duration (April 2020-April 2021, blue line) and comparison with that before the pandemic (orange line); the COVID-19 cases are represented in gray line. (b) COVID-19 daily new cases in our country.
Clinical information of the patients contracting COVID-19 within 1 month after discharge.
| Patients | Age | Gender | Type of surgery | City | Indication | Previous COVID-19 history | Comorbidity | BMI | Duration between the hospital discharge and onset of symptoms | Hospital stay for COVID-19 | ICU stay | Need for intubation | Pulmonary involvement in CT scan (%) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Patient #1 | 65 | Female | THA | Isfahan | OA/primary arthroplasty | No | DM, HTN, CVD, | 22.04 | 7.00 | No | No | No | 20 |
| Patient #2 | 60 | Male | TKA | Isfahan | OA/primary arthroplasty | No | DM, | 40.82 | 10.00 | No | No | No | 15 |
| Patient #3 | 76 | Male | TKA | Isfahan | OA/primary arthroplasty | No | DM, HTN | 40.82 | 14.00 | No | No | No | 0 |
| Patient #4 | 70 | Female | TKA | Isfahan | OA/primary arthroplasty | No | DM, HTN | 28.72 | 9.00 | No | No | No | 10 |
| Patient #5 | 75 | Female | TKA | Isfahan | OA/primary arthroplasty | No | DM, HTN | 29.30 | 10.00 | 10 | 5 | Yes | 30 |
| Patient #6 | 59 | Female | TKA | Isfahan | OA/primary arthroplasty | No | HTN | 20.20 | 6.00 | No | No | No | 20 |
| Patient #7 | 55 | Female | TKA | Isfahan | OA/primary arthroplasty | No | Immune system disease | 25.39 | 4.00 | 5 | 2 | No | 40 |
| Patient #8 | 58 | Female | TKA | Isfahan | OA/primary arthroplasty | No | DM, HTN, Immune system disease | 31.11 | 8.00 | No | No | No | 20 |
| Patient #9 | 61 | Female | TKA | Isfahan | OA/primary arthroplasty | No | HTN | 31.22 | 9.00 | No | No | No | 0 |
| Patient #10 | 67 | Female | TKA | Isfahan | OA/primary arthroplasty | No | CVD, cancer | 29.30 | 12.00 | No | No | No | 15 |
| Patient #11 | 66 | Female | TKA | Isfahan | OA/primary arthroplasty | No | 25.59 | 15.00 | No | No | No | 0 | |
| Patient #12 | 70 | Male | TKA | Isfahan | OA/primary arthroplasty | No | CVD | 32.27 | 22.00 | No | No | No | 0 |
| Patient #13 | 56 | Female | TKA | Tehran | OA/primary arthroplasty | No | HTN, | 37.78 | 14.00 | 10 | 7 | Yes | 30 |
| Patient #14 | 64 | Female | TKA | Tehran | OA/primary arthroplasty | No | DM | 37.89 | 8.00 | No | No | No | 25 |
| Patient #15 | 67 | Female | TKA | Tehran | OA/primary arthroplasty | No | DM, CVD | 20.70 | 9.00 | No | No | No | 20 |
| Patient #16 | 62 | Female | TKA | Tehran | OA/primary arthroplasty | Yes (3 mo before the surgery) | 29.59 | 6.00 | 7 | No | No | 20 | |
| Patient #17 | 68 | Female | TKA | Tehran | OA/primary arthroplasty | No | HTN | 31.25 | 7.00 | No | No | No | 15 |
| Patient #18 | 52 | Female | TKA | Tehran | OA/primary arthroplasty | No | 32.88 | 10.00 | No | No | No | 25 |
BMI, body mass index; CT, computed tomography; THA, total hip arthroplasty; TKA, total knee arthroplasty; OA, ostearthritis; DM, diabetes mellitus; HTN, hypertension; CVD, cardiovascular disease.
Figure 2The duration between the hospital discharge and onset of symptoms for patients contracting COVID-19 after operation.